

Accurately diagnose your patients with **tick-borne diseases** sooner

Get the insights you need with a comprehensive menu of reliable tick-borne disease testing from Quest Diagnostics




Diagnose and manage tick-borne diseases earlier

Ticks and the diseases they carry have spread significantly in the last 2 decades¹

Tick-borne diseases have become a growing problem in the U.S., increasing in prevalence and expanding in geographic range.¹ While Lyme disease is the most common tick-borne illness, there are many types—based on location and causative agent—including both rickettsial diseases, such as anaplasmosis, ehrlichiosis, and Rocky Mountain spotted fever, and non-rickettsial diseases, such as babesiosis and tularemia.

Many of these illnesses can have similar signs and symptoms, including skin rash, fever, and chills—presenting a diagnostic challenge. Adding to that challenge is co-infection with multiple tick-borne diseases, which may be common.² A recent study of more than 3,000 patients with chronic Lyme disease found that over 50% had co-infections, with 30% reporting 2 or more co-infections.³



Geographic areas of prevalent tick species in the U.S.⁴

Testing from Quest can help you make accurate tick-borne disease diagnoses

With more than 30 tick-borne disease tests and panels, including both molecular and serologic testing, Quest can help you make timely, differential diagnoses.

An estimated

300,000

people in the U.S. are diagnosed with Lyme disease each year⁵

Testing helps support accurate, differential diagnoses

Diagnosis of tick-borne disease is primarily based on:

- History of exposure to an area where ticks are endemic
- Clinical presentation

Because tick-related illnesses present similar signs and symptoms, laboratory testing can help confirm clinical diagnosis. Tests include:

- Polymerase chain reaction (PCR)-based assays
- Serologic techniques
- Microscopic visualization
- Culture
- Tick identification




Know specifically which tick-borne diseases your patient may have

CDC guidelines: test to confirm

CDC guidelines for diagnosis of tick-borne diseases recommend lab testing to confirm diagnosis, as treatment may vary by disease type.⁶ Although serologic testing has generally served as the gold standard for tick-borne disease diagnosis, molecular testing can be useful for detecting and differentiating among diseases, particularly in acute cases or within the first week or 2 of illness.⁶

A general pattern for molecular vs. serologic testing⁷



For Lyme disease, the CDC currently recommends a 2-step algorithm for serologic testing:⁸

Step 1

Enzyme immunoassay (EIA) or immunofluorescence assay (IFA)—if negative, no further testing is recommended; if positive or indeterminate, the second step should be performed

Step 2

Immunoblot test—results are considered positive only if the EIA/IFA and immunoblot are both positive

Quest offers a comprehensive tick-borne disease test portfolio

Quest's portfolio of accurate, reliable tick-related tests and panels adheres to CDC guidelines, providing you with the insight you need to:

Make a timely, differential diagnosis Distinguish acute from chronic disease Identify ticks and other arthropods

Quest offers more than 30 tests and panels for the accurate diagnosis and management of tick-borne diseases.

Rely on location, causative agent, and testing to make accurate tick-borne disease diagnoses

Tear off to use as a quick disease overview guide.



Lyme disease

Ticks: blacklegged or deer tick (*Ixodes scapularis*), western blacklegged tick (*Ixodes pacificus*)

Regions: Northeast, Mid-Atlantic, North Central, Pacific Coast

Pathogen: *Borrelia burgdorferi* (bacterium)

Ehrlichiosis

Tick: Lone Star tick (*Amblyomma americanum*)

Regions: Southeast, South Central

Pathogens: *Ehrlichia chaffeensis*, *Ehrlichia ewingii* (bacteria)

Anaplasmosis

Ticks: blacklegged or deer tick (*Ixodes scapularis*), western blacklegged tick (*Ixodes pacificus*)

Regions: Upper Midwest, Northeast, Mid-Atlantic, North Central, Pacific Coast

Pathogen: *Anaplasma phagocytophilum* (bacterium)

Babesiosis

Tick: blacklegged or deer tick (*Ixodes scapularis*)

Regions: Northeast, Upper Midwest, Pacific Coast

Pathogens: *Babesia microti*, *Babesia duncani* (protozoa)

Borrelia miyamotoi disease

Ticks: blacklegged or deer tick (*Ixodes scapularis*), western blacklegged tick (*Ixodes pacificus*)

Regions: Northeast, Mid-Atlantic, North Central, Pacific Coast

Pathogen: *Borrelia miyamotoi* (bacterium)

Colorado tick fever

Tick: Rocky Mountain wood tick (*Dermacentor andersoni*)

Regions: Western U.S., Mountain

Pathogen: Colorado tick fever virus

Q fever

Tick: Rocky Mountain wood tick (*Dermacentor andersoni*)

Regions: Mountain, East North Central, Pacific, West North Central, South Atlantic

Pathogen: *Coxiella burnetii* (bacterium)

Tularemia

Ticks: Lone Star tick (*Amblyomma americanum*), Rocky Mountain wood tick (*Dermacentor andersoni*), American dog tick (*Dermacentor variabilis*)

Regions: West North Central, Mountain

Pathogen: *Francisella tularensis* (bacterium)

Tick-borne relapsing fever (TBRF)

Tick: soft tick (*Ornithodoros*)

Regions: West, South, Southwest

Pathogens: *Borrelia hermsii* and other spp. (bacteria)

Rocky Mountain spotted fever (RMSF)

Ticks: American dog tick (*Dermacentor variabilis*), brown dog tick (*Rhipicephalus sanguineus*), Rocky Mountain wood tick (*Dermacentor andersoni*)

Regions: Mountain, Pacific Coast, Southwest

Pathogen: *Rickettsia rickettsii* (bacterium)

Rickettsia parkeri rickettsiosis (spotted fever)

Tick: Gulf Coast tick (*Amblyomma maculatum*)

Regions: Coastal U.S., along the Atlantic Coast and Gulf of Mexico

Pathogen: *Rickettsia parkeri* (bacterium)


Key considerations for diagnosing tick-borne diseases

- The prevalence of tick-borne diseases is rapidly increasing
- Co-infection may be common
- A high degree of symptom overlap exists amongst these conditions


Knowing where cases have been reported can help you manage tick-borne diseases

The geographical range of tick-borne diseases has expanded—mostly due to the growing deer population—while land that was once cleared for farming has become reforested, attracting more tick hosts (like deer) and more suburban development.¹ Patients' everyday activities now put them in closer contact with wildlife—and ticks.

Lyme disease:
U.S. reported cases, 2015²



Rocky Mountain spotted fever:
U.S. reported cases, 2015²



Note: Each dot represents 1 case. Cases are reported from the infected person's county of residence, not necessarily the place where they were infected.

Note: In 2015, no cases of tick-borne illness were reported from Hawaii. In 2015, Alaska reported 1 travel-related case of Lyme disease and 2 cases of tularemia.



Please contact your Quest Diagnostics sales representative at **1.866.MYQUEST** (1.866.697.8378) for more information about our tick-borne disease testing or visit **QuestDiagnostics.com**.

References

1. National Institutes of Health. Tickborne diseases. Available at www.niaid.nih.gov/diseases-conditions/tickborne-diseases. Accessed April 27, 2017.
2. The Centers for Disease Control and Prevention. Tickborne diseases of the United States: a reference manual for health care providers. Fourth edition, 2017. Available at www.cdc.gov/lyme/resources/tickbornediseases.pdf. Accessed June 13, 2017.

Make timely, differential tick-borne disease diagnoses with comprehensive testing from Quest

Test Name	Test Code	CPT Code(s)*
<i>Anaplasma phagocytophilum</i> Antibodies (IgG, IgM) [†]	34464(X)	86666 (x2)
<i>Anaplasma phagocytophilum</i> DNA, Qualitative Real-Time PCR [†]	17320	87798
<i>Anaplasma phagocytophilum</i> and <i>Ehrlichia chaffeensis</i> Antibody Panel [†]	10611(X)	86666 (x4)
<i>Babesia duncani</i> (WA1) Antibody (IgG), IFA	17231	86753
<i>Babesia microti</i> DNA, Real-Time PCR [†]	37314	87798
<i>Babesia microti</i> Antibodies (IgG, IgM), IFA [†]	34300	86753 (x2)
<i>Borrelia hermsii</i> Antibody Panel, IFA [†]	34690	86619 (x2)
<i>Borrelia miyamotoi</i> DNA, Real-Time PCR, Miscellaneous [†]	93795	87798
<i>Borrelia miyamotoi</i> DNA, Real-Time PCR, Tick [†]	93794	87798
Colorado Tick Fever Antibody Panel, IFA	34986	86790 (x2)
<i>Ehrlichia chaffeensis</i> (IgG, IgM) [†]	34271(X)	86666 (x2)
<i>Ehrlichia chaffeensis</i> DNA, Real-Time PCR	11353	87798
<i>Ehrlichia ewingii</i> DNA, Real-Time PCR ^{††}	43300	87798
Febrile Antibodies Panel [†]	91121	86757 (x4), 86622 (x2), 86768 (x5)
Febrile Antibodies and <i>Francisella</i> Panel [†]	91122	86757 (x4), 86622 (x2), 86768 (x5), 86000
<i>Francisella tularensis</i> Antibody, Direct Agglutination (DA)	35176	86000
<i>Francisella tularensis</i> Screen	10443(X)	87081
Lyme Disease Ab with Reflex to Blot (IgG, IgM)	6646	86618
Lyme Disease Antibodies (IgG, IgM), Immunoblot	8593	86617 (x2)
Lyme Disease Antibody (IgG), Immunoblot	29477	86617
Lyme Disease Antibodies (IgG, IgM), IBL, CSF	70028	86617 (x2)

Test Name	Test Code	CPT Code(s)*
Lyme Disease (<i>Borrelia spp</i>) DNA, Qualitative, Real-Time PCR, Blood [†]	15777	87801
Lyme Disease (<i>Borrelia spp</i>) DNA, Qualitative, Real-Time PCR, CSF/ Synovial Fluid [†]	15564	87801
Lyme Disease (<i>Borrelia spp</i>) DNA, Qualitative, Real-Time PCR, Urine [†]	15868	87801
Real-Time PCR, Tick, Tick ID with Reflex to Lyme Disease DNA	90558	87168
Lyme Disease (<i>Borrelia spp</i>) DNA, Qualitative, Real-Time PCR, Tick [†]	15510	87801
Lyme Disease Antibody Index for CNS Infection	34194	82040, 82042, 82784 (x2), 86618 (x4)
Malaria/Babesia/Other Blood Parasites	831	87207
Q Fever (<i>Coxiella burnetii</i>) Antibodies (IgG, IgM), with Reflex to Titers	37071	86638 (x4)
<i>Rickettsia</i> (RMSF) Antibodies (IgG, IgM) with Reflex to Titers	6419	86757 (x2)
<i>Rickettsia</i> Antibody Panel with Reflex to Titers	37507	86757 (x4)
<i>Rickettsia conorii</i> Antibody Panel, IFA [†]	15332(X)	86757 (x2)
<i>Rickettsia</i> (Typhus Fever) Antibodies (IgG, IgM) with Reflex to Titers	37503	86757 (x2)
<i>Rickettsia rickettsii</i> DNA, Real-Time PCR [†]	70191	87798
Rickettsial Disease Panel	37478	86638 (x4), 86757 (x4)
Tick (and Other Arthropods) Identification	3946(X)	87168

NEW: Tick-Borne Disease, Acute Molecular Panel **94322** **87798 (x4), 87801**

* The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

** Available from Quest Diagnostics Infectious Diseases, Inc.

† This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

‡ Available from Quest Diagnostics Nichols Institute, Chantilly, VA.



Please contact your Quest Diagnostics sales representative at **1.866.MYQUEST** (1.866.697.8378) for more information about our tick-borne disease testing or visit **QuestDiagnostics.com**.

References

1. National Institute of Health. Tickborne diseases. Available at www.niaid.nih.gov/diseases-conditions/tickborne-diseases. Accessed April 27, 2017.
2. Lymedisease.org. About Lyme disease co-infections. Available at www.lymedisease.org/lyme-basics/co-infections/about-co-infections. Accessed May 16, 2017.
3. Johnson L, Wilcox S, Mankoff J, et al. Severity of chronic Lyme disease compared to other chronic conditions: a quality of life survey. *PeerJ*. 2014;2:e322.
4. The Centers for Disease Control and Prevention. Geographic distribution of ticks that bit humans. Available at www.cdc.gov/ticks/geographic_distribution.html. Accessed May 5, 2017.
5. The Centers for Disease Control and Prevention. How many people get Lyme disease? Available at www.cdc.gov/lyme/stats/humancases.html. Accessed April 24, 2017.
6. The Centers for Disease Control and Prevention. Tickborne diseases of the United States: a reference manual for health care providers. Fourth edition, 2017. Available at www.cdc.gov/lyme/resources/tickbornediseases.pdf. Accessed June 13, 2017.
7. The Centers for Disease Control and Prevention. CDC public health grand rounds: emerging tickborne diseases. 21 Mar 2017. Available at www.cdc.gov/cdcgrandrounds/archives/2017/March2017.htm. Accessed June 13, 2017.
8. Centers for Disease Control and Prevention. Lyme disease: two-step laboratory testing process. Available at www.cdc.gov/lyme/diagnostictesting/labtest/twostep/index.html. Accessed July 20, 2017.

QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2017 Quest Diagnostics Incorporated. All rights reserved. SB7043 10/2017